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Novel Y-chromosomal 
microdeletions associated with 
non-obstructive azoospermia 
uncovered by high throughput 
sequencing of sequence-tagged 
sites (STSs)
Xiao Liu1,9,*, Zesong Li3,*, Zheng Su1,*, Junjie Zhang5,*, Honggang Li4, Jun Xie2, Hanshi Xu1,7, 
Tao Jiang1, Liya Luo3, Ruifang Zhang1, Xiaojing Zeng1, Huaiqian Xu6, Yi Huang3, 
Lisha Mou3, Jingchu Hu1, Weiping Qian2, Yong Zeng8, Xiuqing Zhang1, Chengliang Xiong4, 
Huanming Yang1, Karsten Kristiansen9, Zhiming Cai3, Jun Wang1 & Yaoting Gui2
Y-chromosomal microdeletion (YCM) serves as an important genetic factor in non-obstructive 
azoospermia (NOA). Multiplex polymerase chain reaction (PCR) is routinely used to detect YCMs by 
tracing sequence-tagged sites (STSs) in the Y chromosome. Here we introduce a novel methodology in 
which we sequence 1,787 (post-filtering) STSs distributed across the entire male-specific Y chromosome 
(MSY) in parallel to uncover known and novel YCMs. We validated this approach with 766 Chinese 
men with NOA and 683 ethnically matched healthy individuals and detected 481 and 98 STSs that 
were deleted in the NOA and control group, representing a substantial portion of novel YCMs which 
significantly influenced the functions of spermatogenic genes. The NOA patients tended to carry more 
and rarer deletions that were enriched in nearby intragenic regions. Haplogroup O2* was revealed 
to be a protective lineage for NOA, in which the enrichment of b1/b3 deletion in haplogroup C was 
also observed. In summary, our work provides a new high-resolution portrait of deletions in the Y 
chromosome.
Male infertility affects approximately 7% of the general population, and spermatogenic failure accounts for the 
majority of these cases. Non-obstructive azoospermia (NOA) is a severe state of spermatogenic failure (SSF) that 
affects 10% of infertile men and is diagnosed in 60% of azoospermic men1. The etiologies of NOA are thought 
to include genetic disorders, such as sex-chromosome abnormalities, Y chromosomal microdeletions (YCMs) 
and translocations, cryptorchidism, testicular torsion, radiation and toxins1,2. YCM is the most important 
genetic etiology of male infertility and has been extensively studied3–5. Over the last decade, varying extents of Y 
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chromosome microdeletions have been identified. These microdeletions are clustered in three primary regions 
termed AZFa, AZFb, and AZFc6. Common deletions sites include AZFa, AZFb, AZFc, AZFab, AZFac, AZFbc and 
AZFabc. Most of these recurrent deletions result from non-allelic homologous recombination (NAHR) between 
near-identical amplicons, including gr/gr, b1/b3, and b2/b3, which are partial deletions that occur within or near 
the AZFc region7,8.
Currently, the detection of Y chromosome deletions is commonly adopted for diagnostic and prognostic pur-
poses, and is demonstrated its essentialness9,10. In clinical practice, the European Academy of Anthrology (EAA) 
and the European Molecular Genetics Quality Network (EMQN) have published a guideline11 that adopts the use 
of 6 sequence-tagged sites (STSs) to detect AZF complete deletions and recently have revised the guideline by 
adding extensional analysis on a few additional STSs12. Twenty to 30 STSs have been suggested to be sufficient for 
providing good coverage of the important regions of the Y chromosome13,14. Recently, novel functional Y chro-
mosomal partial deletions have been recurrently reported. The majority of the studies have focused on single-plex 
or multiplex PCR with limited STS primers. The complex structure of the AZF region, which is composed of 
massive, near-perfect amplicons, poses special challenges for the sequencing of the region and subsequent char-
acterization of the deletions that affect the region.
The emerging technique of next generation sequencing (NGS) provides a unique opportunity to depict the 
whole portrait of Y chromosome deletions. Whole genome sequencing (WGS), including whole Y chromosome 
sequencing, has enabled the tracking of Y chromosomal variations including deletions. However, the majority 
of deleterious deletions are dispersed along the ampliconic regions (especially in eight palindromes) that consist 
of a total of 5.7 Mb or 25% of the MSY euchromatin, which creates a technological difficulty for WGS because 
this method requires mapping based on short reads, and these regions are usually filtered for further analyses15. 
Nevertheless, focusing on only the numerous STSs within the palindrome rather than the entire sequences pro-
vides unique landmarks that can be used to track deletions. This set of STSs in combination with the NGS tech-
nique is perfectly suited for the identification of deletions across the Y chromosome.
To track the overall deletion status and prevalence across the whole Y chromosome, we collected all of the 
unique and low-copy number STSs of the Y chromosome in the database and designed probes to capture and 
sequence all of them on the NGS platform. A total of 2260 (1787 post-filtering) STSs dispersed along the Y chro-
mosome were captured and further sequenced. We carefully recruited 766 patients (post-filtering) with NOA 
and excluded those with complete AZFa, AZFb or AZFc deletions (see the Methods for details) and 683 matched 
controls (post-filtering) with normal fertility histories from the Chinese population to test all of the STSs. In 
this study, we first developed a novel algorithm to detect deletions in our dataset and validated its high level of 
accuracy with various experimental approaches (Fig. 1). We then carefully compared the deletions and the hap-
logroups between the NOA and controls. Finally, we depicted the whole deletion portrait and the characteristics 
of our dataset. A few novel and significant Y deletions were also carefully described.
Result
Data production. We selected 2260 STSs that are dispersed across the entire euchromatic region of the 
male-specific Y chromosome (Supplementary Table 1 and Fig. 2a). Taken together, the STS sequences constituted 
846,000 bp of the target region. One thousand four hundred and eighty-five Y chromosomes, including 774 from 
patients with NOA and 711 from healthy controls, were sequenced with Hiseq2000, and mean data amount was 
25.27 Mb per sample. On average, each sample was sequenced with a mean coverage of 38.25x, and 95.86% of the 
target region was covered by at least one read (Supplementary Table 2).
Method development and evaluation of the detection of  Y-chromosomal microdele-
tions. Data alignment, filtering and normalization. Deleted STSs should have significantly lower read cov-
erage than undeleted STSs, but the reads for the deleted STSs are not usually zero due to non-specific capture, 
sequencing and misalignment effects, so sequencing depth can serve as an informative signal for deletion detec-
tion. To fully utilize this information, we derived three metrics from the sequencing depth for use as predictors 
and developed a pipeline to detect STS deletions that utilized the support vector machine (SVM) model (Fig. 1).
For data quality control, the sequencing reads were filtered to remove low-quality and duplicated reads and 
were then aligned to the reference genome. The mean and median depth of each sample and STS, as well as the 
depth distribution of each STS and sample, were calculated. Due to the abnormal efficiency of the probes for the 
capture of certain STSs (GC bias effect etc.) or other issues, such as sample quality, the mean depths of certain 
STSs and samples deviated from the normal range; for example, extremely low STS and sample levels with depths 
outside of the 1.5x interquartile range were filtered as outliers to reduce the possibility of false positive detection. 
Twenty-five samples and 175s STS were removed in this stage (Fig. 1). Additionally, we observed that there was 
sufficient statistical power to qualify a STS for deletion identification only when the depth distribution of that 
STS was sufficiently high among all of the samples, i.e., when the STS performed well in terms of the capture of 
undeleted samples. After data modeling (data not shown), we set up a more stringent cutoff of 15x for the median 
depths of the STSs, and an additional 298 STS were filtered. The variation in the data production for each sample 
was normalized by dividing the depth of each STS by the mean depth of that particular sample. Furthermore, 
substantial depth variation across all of the STSs in one sample reflected an inefficiency of the experiment for the 
sample. Such samples would adversely affect the accuracy of the deletion judgment. Therefore, a filter < 0.7 was 
applied to the standard deviations of the normalized depths, which resulted in the filtering of 11 samples; thus, 
1449 samples (97.6%) and 1787 STSs (79.0%) were qualified for the next step.
Deletion detection. For each STS, three metrics derived from the sequencing depth were used as predictors to fit 
a support vector machine (SVM) model for state classification. Enlightened by the normal distribution approx-
imation for the depth distribution of the STSs in the total sample set (excluding the outliers), we calculated the 
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logarithm of the probability of each STS under the approximated normal distribution, which was scaled to be 
centered on 0 and had a standard deviation of 1; this measure provided the first metric. The other two metrics 
were the ratio of the mean depth of the STS to the median depth of the same STS across all samples (depth/RMD) 
and the ratio of the mean depth of the STS to the median depth of all STSs in that sample (depth/SMD). Details 
are provided in the Methods section.
To train the SVM model, a total of 134 randomly selected STSs from 26 samples that covered different p 
values, depth/RMD and depth/SMD values were selected to perform the PCR validation to reveal their microde-
letion states and were used as a training data set for the SVM model (Supplementary table 3). In the SVM model, 
a Gaussian radial-based kernel were used, and its parameters were selected by a grid search with exponentially 
growing C and sigma. This process was performed via cross validation using the training dataset. The concord-
ance rates for the different C and sigma are illustrated in Supplementary Fig. 1, and the best combination of 
C = 2^9 and sigma = 2^3 was selected. With this combination, the SVM model perfectly classified the training 
samples.
Next, we used the trained SVM classifier to detect the STS deletions in all of the samples. Overall, 1020 dele-
tions in 87 NOA patients and 264 deletions in 71 normal donors were identified by our method (Table 1 and 
Supplementary Table 4).
Figure 1. Flowchart of the detection of YCMs in this study. 
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Accuracy evaluation. To validate our results, we first examined the statuses of the two control STSs in our 
dataset (sY84 and sY86, see Methods), and no deletions were detected by our method in any of the samples 
as expected. Furthermore, 89 events that included both deletions and non-deletions from 17 STS and from 16 
samples were randomly selected for the PCR validation, and a high validation rate of 97.8% (87/89) was achieved 
(Supplementary Table 5 and Supplementary Table 6). We also used the frequently deleted STS sY1191 to estimate 
our false negative detection rate. Four of one hundred random controls and 7/100 NOAs deleted by PCR were all 
detected in our method. Finally, we found that all of the Y chromosomes belonging to haplogroup N had a b2/b3 
deletion in our dataset, and this finding is consistent with that of a previous report8, which implies the accuracy 
of our method for the detection of deletions and haplogroup clustering.
NOA patients carry more and rarer deletions that are enriched in gene regions. Overall, 87 
NOA patients were identified as having at least one deleted STS, and these patients constituted 11.4% of the 
Figure 2. Distributions of the STS markers and deletions in the Y chromosome. (a) The density distribution 
of the STS markers targeted in our study and (b) the density distributions of the STS deletions in the NOA 
patients (c) and the normal group across the Y chromosome. (d) Illustrations of novel deletions from samples 
w529 and w140. The densities were calculated for every 100 kb window.
NOA Normal P value
Number of samples 766 683 NA
no deletion 679(88.6%) 612(89.6%) NA
any deletion 87(11.4%) 71(10.4%) 5.8 × 10−1*
unique deletion number 481 98  <2.2 × 10−16*
post-merge unique deletion 121 86 NA
Average unique deletion per deleted 
individual 5.5 1.4 NA
total deletion number 1,020 264  <2.2 × 10−16*
Average individuals per unique deletion 
(SD) 2.1(4.8) 2.7(6.4) 7.4 × 10
−16**
average deletion number per deleted indi-
viduals (SD) 11.7(27.2) 3.7(7.1) 6.4 × 10
−4**
Table 1. Statistics for the deletions in the NOA patients and normal individuals. *Chi square test. **Kruskal-
Wallis test. NA indicates not applicable.
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total of 766 cases. In contrast, this number was lower in the control group (71/683, 10.4%), but the difference 
was not significant (P = 0.5797, table 1). Comparison of the total deleted STSs in the NOA and control groups 
revealed that significantly more STSs were deleted in the NOAs than in the controls (1020 vs. 264, P < 2.2E-16). 
The average deletion numbers of the individuals with NOA and the control group also exhibited a significant 
difference (11.7 vs. 3.7, P < 0.001), with a 3.2-fold increase in the NOA patients. This trend is clearly illustrated 
in Fig. 3a. Although the majorities of the individuals in both groups had fewer than 5 deleted STSs, the distri-
bution curves were obviously inclined toward a larger number of deletions in the case group than the controls. 
Three NOA patients had more than 75 STS deletions, while none of the control samples had similar numbers of 
deletions. Interestingly, in addition to the hotspots in AZF regions that were present in both the case and control 
groups, the deleted STSs of the cases tended to be aggregated, while those in the controls tended to be dispersed 
(Fig. 2b,c). After connecting the deleted STSs (see Methods), the unique deletions in the NOAs were significantly 
reduced from 481 to 121, whereas no significant shrinkage was observed in the controls (98 to 86). These findings 
demonstrated the aggregated nature of the deletions in the NOA group. Furthermore, these deleted STSs were 
significantly enriched near the coding sequences (defined as sharing an overlapping base pair, p < 0.001) and the 
genes (p < 0.0001) in the NOA group compared with the controls. The deletions in the controls tended to occur 
in intergenic regions (P < 0.05). Indeed, we found that none of the deleted STSs in the controls was located in the 
coding or UTR regions on the Y chromosome (Fig. 4 and Supplementary Table 7). In summary, NOA patients 
typically carry large deletions that constitute numerous continuous STSs and would induce the loss of functional 
genes or gene copies, whereas the deletions in the controls tended to be short deletions that involved fewer STSs 
and functional genes.
The NOA and control groups exhibited 481 and 98 unique STS deletions, respectively, and the difference was 
significant (P < 2.2 × 10−16, chi Square test). Examination of the recurrences or frequencies of these STS revealed 
that the average number of NOAs who carried each unique deletion was 2.1, and this value was significantly lower 
than the average of 2.7 per deletion observed in the control group (P = 7.4 × 10−16, Kruskal-Wallis test, Table 1). 
The frequency distribution of each deleted STS revealed that more than 80% of the deletions in the NOA group 
were unique and only occurred in one individual (Fig. 3b). Further analysis confirmed that these unique deletions 
represented several long-range deletions with functional importance. In contrast, in the control group, more than 
half of the deletions were recurrent and scattered in the Y chromosome. Interestingly, the NOAs carried more 
recurrent deletions with high frequencies (harbored by more than 5 samples) than the controls, and a detailed 
investigation revealed that these deletions were located in the AZFc region (DAZ gene deletion). This issue is 
discussed in detail below.
Our STS markers were spread across all of the ampliconic regions of the Y chromosome and were intensively 
colonized with Yp and the large palindromic segments from P1 to P8 that spanned the azoospermia factor (AZF) 
genes (Fig. 2a). The prevalence of deletions across the Y chromosome revealed specific patterns in the NOA and 
control samples (Fig. 2b,c). First, AZFc harbored several recurrent interstitial deletions, and their frequencies in 
the NOA group were higher than those of the control group. Second, there were some long-range continuous 
deletions that were in Yp, but this only occurred in the NOAs. Gene analysis revealed that these deletions were 
enriched in the gene-rich regions and that the majority of these deletions influenced specific single-copy genes 
or gene copies of specific gene families. Moreover, some of these deletions might even have caused the loss of 
the functions of all of the gene copies. Gene copies, including TSPY in Yp, RBMY in AZFb and DAZ in AZFc 
(Table 2), were lost. In contrast, the deleted STSs in the controls were more likely to be located in the gene desert 
of the Y chromosome.
Figure 3. NOA patients carry more but rarer deletions. (a) The non-cumulative distributions of the STS 
deletion frequencies in the NOA patients and controls. The X-axis indicates the number of deleted STS found 
in each individual, and the Y-axis indicates the proportions of individuals who carried the each number of STS 
deletions in that window. The red and blue bars indicate the NOA patients and the normal group, respectively. 
(b) The recurrence of the STSs that were deleted in each group. The X-axis indicates the number of individuals 
with deleted STSs, and the Y-axis indicates the proportion of the total unique STSs that were deleted in the 
respective numbers of individuals. The red and blue bars indicated the NOA and normal groups, respectively.
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Known and novel deletions and their relationships with NOA. In our study, the deletions were 
detected with no prior knowledge. After connecting the deleted STSs, we were able to identify a substantial por-
tion of the known/published YCMs, and the majority of these YCMs were in AZF regions (with the exception 
of gr/gr for which the only marker STSs, i.e., sY1291 and sY1189, were filtered in our dataset). To confirm the 
reliability of our categorization of the AZF partial deletions, particularly the most abundant AZFc deletions, we 
performed PCR for sY1191, sY1192, sY1291 and sY1189 to differentiate the partial AZFc deletions5, and the 
results were fully consistent with the sequencing classification. In our NOA samples, the most abundant AZFc 
deletions were b2/b3 (7.0%) followed by b1/b3 (0.91%). In addition to the known YCMs, two small deletions 
were identified in AZFa and AZFb (Table 2 and Supplementary Table 4). These deletions influenced none of the 
three major genes, i.e., USP9Y, DBY (DDX3Y) and UTY, in the AZFa region and only influenced the partial cop-
ies of CDY in the AZFb region. These deletions were found in both the NOAs and controls and were most likely 
polymorphic and not involved in male reproduction. Interestingly, we found two novel forms of AZFc partial 
deletion. The first was carried by two NOAs and deleted all the STSs from b1 to b2 along with sY1191 and sY1192, 
whereas the deletion retained sY1291 and sY1189. It is most likely that this unusual b1/b3 deletion arose from 
a gr/rg inversion (Table 2 and Fig. 5a). The other novel deletion was a b1/b2 deletion (Table 2 and Fig. 5b) that 
was carried by two of the NOA patients (0.26%), and one of these patients had Sertoli-cell-only syndrome. This 
deletion was further validated by PCR. The b1/b2 deletion caused a partial loss of the RBMY gene copies and the 
complete loss of the PRY copies, which might impact spermatogenesis. Additionally, we identified a novel form 
of an entire DAZ gene deletion that would have been falsely defined as a gr/gr deletion with limited STS PCR 
(Table 2 and Fig. 5c). Five NOA patients (0.65%) were absent all of the DAZ gene copies, while the majority of the 
nearby genes were unaffected.
Two novel, massive deletions were specifically detected in the NOA patients and merit particular attention. 
Both patients had the normal karyotype of 46, XY. The patient with w529 had a testicular volume of 15 ml, and 
the testicular biopsy and histological analysis revealed that the development of his sperm cells was arrested in 
the spermatocyte stage. We identified two massive deletions separated by a distance of 1.1 Mb and with a total 
size of approximately 3.37–3.86 Mb in the Yp chromosome of this patient (Fig. 2d and Table 2). These deletions 
affected the functions of several protein-coding genes, including PCDH11Y, PRKY and TSPY. Notably TSPY is 
thought to function in early spermatogenesis and to be involved in the differentiation and proliferation of the 
spermatogonia-spermatocyte transition16. Patient w140, who had a soft testis with the small size of 6 ml, exhibited 
a discrete deletion from the proximal IR2 that included the b1/b2 and gr/gr regions (Fig. 2d and Table 2). This 
significant deletion spanned approximately 2.5 Mb and disrupted all of the genes copies of RBMY and PRY and 
the partial copies of DAZ and CDY. The RBMY gene in the AZFb region has long been considered to be vitally 
functional in spermatogenesis and reported to be deleted in a couple of patients with spermatogenic failure17. The 
deletion of this gene in combination with a gr/gr deletion which is a risk factor for spermatogenic failure5, might 
have induced this severe case. The deleted STSs in all of the samples are listed in Supplementary Table 4.
Y haplogroups and deletions. Several studies have reported associations of certain Y haplogroups with 
male infertility18–21, while others have opposed this this observation22. With the help of our substantial sequenc-
ing coverage and the ability to capture the flanking sequences of the target STSs, we were able to call SNPs in 
the Y chromosome, including substantial markers, to determine the Y haplogroups. We attempted to assign our 
samples to haplogroups based on updated markers to differentiate the Y haplogroup tree linage23 and were able 
to assign 589 NOA patients and 569 normal controls into 9 major Y haplogroups and 5 additional sub-lineages 
Figure 4. NOA deletions were enriched near intragenic regions. Intragenic regions are a combination of 
coding, UTR and intronic region, and the p values were calculated by Chi square tests, which were listed on top 
of the bars.
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in haplogroup O (Table 3). Complete information for the marker SNPs in the remaining samples were not 
confidently recovered and were thus excluded from further analysis. The majority of our samples were spread 
Region AZFa***† AZFb***†
AZFc
Yp†b2/b3 b1/b3 b1/b2† DAZ deletion†
NOA
fre-
quency 2(0.26%) 1(0.13%) 1(0.13%) 54(7.0%) 7(0.91%)** 2(0.26%) 5(0.65%) 1(0.13%)
sample 
ID
W606, 
W635 W600 W140 *
W306,W344,W135,W047.
W241,W451,W688 W563,W216
W074,W1404,W141,W315, 
W461 W529
Normal
fre-
quency 1(0.15%) 1(0.15%) 0 42(6.1%) 2(0.29%) 0 0 0
sample 
ID 1074 247 * 1871,1973
Major 
genes 
affected
CDY RBMY, PRY, DAZ, CDY DAZ, CDY RBMY, PRY, DAZ RBMY, PRY DAZ
TSPY, RBMY, 
PCDH11YPRKY
Table 2. Known and novel deletions identified in our study. *Details not indicated. **Includes two b1/b3 
deletions (W451 and W688) with the gr/rg inverted organization. ***Indicates that various forms of partial 
deletions occurred within the AZFa or AZFb regions. †Novel deletions
Figure 5. Illustration of the novel deletions. (a) Illustration of the b1/b3 deletion in the reference organization 
and the proposed structure of the b1/b3 deletion with an gr/rg inverted organization. (b) Illustration of the  
b1/b2 deletion in the reference organization. (c) Illustration of a DAZ deletion. The deletion statuses of the STS 
markers are marked, and “+ ” indicates “not deleted”, and “− ” indicates “deleted”.
www.nature.com/scientificreports/
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among the haplogroup O, C, N and Q, and the greatest proportion belonged to haplogroup O (74.4% among 
the NOAs and 79.1% among the normal controls), supporting the high prevalence of this haplogroup in East 
Asia. Association analysis revealed that haplogroup O2* seemed to be a lineage that was protective against NOA 
(Table 3, P = 1.6 × 10−3, Fisher’s exact test), while the O1a2 haplogroup was only marginally associated to be sus-
ceptible (P = 0.035). In light of the discoveries of the enrichment of certain YCMs in certain Y haplogroups due 
to founder mutations that led to deletions, such as that of b2/b3 in haplogroup N and gr/gr in haplogroup D2b7, 
we intended to identify new association between the haplogroups and the deletions. Heatmaps were drawn for 
the STS deletion distributions of each haplogroup separately for the NOA and normal cohorts (Supplementary 
Fig. 2 and Supplementary Fig. 3). The observed deletion numbers were tested to determine whether they were 
significantly over-represented or under-represented relative to the expected numbers. The three STS deletions 
DYF155S1, RH102047 and sY1191 were part of the b2/b3 deletion, which was significantly enriched in hap-
logroup N among both the NOAs and the controls, as reported previously. Interestingly, we identified a few STS 
deletions that were significantly enriched in haplogroup C among the NOAs, and all of these STSs actually rep-
resented b1/b3 deletions, which implies the existence of an unidentified sub-lineage in haplogroup C that might 
feature the b1/b3 deletion. The exact deletion numbers and the calculated P value are listed in Supplementary 
Table 8 and 9.
Discussion
Our work represents the first study to utilize next generation sequencing (NGS) of a high density of STS mark-
ers to fine map the high polymorphic deletions/microdeletions across male-specific Y chromosome (MSY) in 
both non-obstructive azoospermic and fertile populations. From FISH to multiplex/single-plex STS-based PCR, 
numerous methods have been proposed for the detection of Y chromosome deletions, including real time PCR24 
and array CGH25. The key focus of these method developments is improving sensitivity and resolution. In a 
clinical setting, including more STS markers may not be justified in terms of cost and the relevance to clinical 
interpretation. Nevertheless, increasing the resolution of the current understanding of YCMs in different popu-
lation, particularly the rare/partial deletions that are associated with spermatogenic failure, is highly attractive. 
Furthermore, a limited number of STS markers would occasionally induce false positive detections in cases in 
which the SNP exists in the primer annealing position26, but the addition of more markers in the same region 
would decrease this possibility. Our method combines the low cost/high throughput of the NGS technique with 
easy to use of STS markers to depict the most comprehensive and highest resolution landscape of YCMs to date, 
which significantly enhances our understanding of the field. Our method involves the sequencing of less than 1 
million target bases but compromises almost two thousand STSs and thus balances resolution and cost. On one 
hand, compared with the traditional PCR-based approach with limited STS markers, our method not only signif-
icantly increases the resolution to allow for precise detection of the boundaries of the deletions but also provides 
nucleotide information for short-variation detection, which helps to assign Y haplogroups. On the other hand, 
compared with the whole genome or the Y chromosome sequencing, our method not only removes the difficulty 
of short-read alignments to repetitive and palindromic regions to allow for the detection of deletions within 
these regions but also greatly reduces the cost. The cost of sequencing with our method is just 1/50 of that of 
whole exome sequencing and 1/1000 that of whole genome sequencing. In summary, we have provided a realistic 
method for profiling high-resolution YCMs at the population level.
Cases with complete AZFa, AZFb or AZFc deletions, which are known to have significant clinical implication 
in spermatogenic failure, were excluded from our study. The aim of our study was to uncover novel deletions 
inside and outside of the AZF regions, including partial AZF deletions in the population and particularly those 
that may be involved in the genetics of NOA. Previous study has reported novel partial AZFc deletions other than 
b1/b3, b2/b3 and gr/gr in men with azoospermia or severe oligozoospermia, and some of them may be associ-
ated with sperm count27. The large sample size and fine resolution of our data did provide a population-scale 
Y Haplogroup sub-lineage NOA Normal P value*
J 2(0.3%) 2(0.3%) 1
T 1(0.1%) 0 1
N 45(7.6%) 34(6.0%) 2.9 × 10−1
Q 28(4.8%) 16(2.8%) 9.2 × 10−2
C 63(10.7%) 47(8.3%) 1.6 × 10−1
D 10(1.7%) 14(2.5%) 4.1 × 10−1
R 2(0.3%) 5(0.9%) 2.8 × 10−1
G 0 1(0.2%) 4.9 × 10−1
O
O2* 0 9(1.6%) 1.6 × 10−3
O3a 394(66.9%) 388(68.2%) 6.6 × 10−1
O2a 41(7.0%) 42(7.4%) 8.2 × 10−1
O2b 2(0.3%) 4(0.7%) 4.4 × 10−1
O1a2 1(0.2%) 7(1.2%) 3.5 × 10−2
total 589 569
Table 3. Y haplogroup distributions of the NOA patients and the normal controls. *Fisher’s exact test, one 
sided.
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portrait of YCMs and identify substantial novel NOA-specific YCMs. Some of these YCMs, such as b1/b2 and 
DAZ deletion, couldn’t arise from homology-mediated recombination, but are more likely to result from liga-
tion of DNA break ends through non-homologous end joining or microhomology-mediated end joining DNA 
repair pathways27–29. The frequency of complete AZF deletion in infertile men (azoospermia and oligospermia) 
is approximately 10% in the East Asian population12, although the corresponding figure is not available for NOA. 
Excluding complete AZF deletions, the frequency of NOA with deletions was 11.4% in our data; therefore, we 
speculate that the total frequency of NOA with any deletions should be approximately 20%. This figure indicates 
a high prevalence of YCMs as genetic etiologies of NOA. Strikingly, we reported that 10.4% of fertile men had at 
least one STS deleted in the Y chromosome. This number is significantly higher than that previously reported and 
expected, and this difference is clearly attributable to our adoption of extensive STS markers. Although our anal-
ysis revealed that the deletions in fertile men usually involved fewer and more recurrent STSs, and few of these 
deletions directly removed genes or gene copies, considering that these deletions span at least several hundred 
base pairs, this extraordinary phenomenon reflects the fragility of the Y chromosome. The deletions found in the 
fertile population may be considered frequent polymorphisms and could also be risk factors for other diseases, 
such as cancer, with higher rates of mortality30. Such deletions could also induce functional deletions in the next 
generation as has been reported for partial AZFc deletions, which are a risk for complete AZFc deletion31. The 
deletions in the NOA patients reflect much more functional significance and the involvement of gene regions. 
As stated previously, more than 80% of the deletions in the NOAs were unique. An unanswered question is thus 
whether these deletions were inherited from the patients’ fertile fathers and serve as rare variants/polymorphisms 
that are involved in the dysfunction of male spermatogenesis with very high penetrance or whether they occurred 
as de novo deletions. Unfortunately, we were not able to access the genetic material of the fathers of the patients 
to clarify this issue. Considering the rarity of novel NOA-related deletions, the samples size should be further 
increased to uncover many more discoveries.
The frequencies and genetic risks of common AZFc deletions related to spermatogenic failure have been 
extensively studied5,31–33. In our NOA sample, the most abundant AZFc deletions were b2/b3 (7.0%) followed by 
b1/b3 (0.91%) and b1/b2 (0.26%). The frequency of the b2/b3 deletion varies between different populations, but 
nearly every individual in haplogroup N was determined to carry this deletion8. The high frequency of the b2/b3 
deletion in our study was mostly due to the prevalence of haplogroup N. Excluding these samples dramatically 
reduced the frequency of the b2/b3 deletion to 1.2% in both the NOA patients and normal controls, which is 
consistent with the results of a previous report5. The effect of the b2/b3 deletion on spermatogenic failure remains 
controversial29, and some groups have found that b2/b3 deletion is a risk factor and is associated with spermato-
genic failure32,34. In our study, although the frequency of the b2/b3 deletion was higher in the NOA patients than 
the normal controls (7.0% vs. 6.1%), no significant difference was observed (P > 0.2, chi square test), and the 
exclusion of haplogroup N provided a similar conclusion (1.2% vs. 1.2%). Our result supports the conclusions of 
a previous large-scale study5.
Our deletion picture consists of many novel deletions with clinical implications and etiological mechanisms 
that remain to be investigated. Specifically, regarding the deletions only observed in the NOA patients, it was nec-
essary to include the related STSs in the panel to screen the large cohort for spermatogenic failure. We believe cer-
tain of the deletions are recurrent with high clinical penetrance. Our database could serve as a valuable resource 
for future investigations into deleterious YCMs, and this database should be further expanded by sequencing 
more infertile men and more general population subjects with our method.
Methods
Samples selection. All of the peripheral blood samples were collected from the Peking University Shenzhen 
Hospital and the Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science 
and Technology. NOA patients were only recruited to the study if they met the following criteria: no sperm 
detected in the pellets of semen samples taken on three different occasions; no inflammation or injury of the 
reproductive system or pelvic cavity; and no karyotypic abnormality or known Y-chromosomal microdeletion. 
The Y-chromosomal microdeletions were detected as described previously11. Specifically, sY84 and sY86 for were 
examined in the AZFa region and sY127 and sY134 were examined in the AZFb region and combined with sY254 
and sY255 in the AZFc region, the results were used to screen for complete deletions involving AZFa, AZFb and 
AZFc. Testicular biopsy and histological analysis were conducted for the azoospermic men whenever possible. 
All of the control men had fathered at least one child without assisted reproductive techniques, such as IVF, ICSI 
and IMSI. This study was approved by the ethical committees of Peking University Shenzhen Hospital and Tongji 
Medical College, and all participants signed a consent form permitting the collection and use of their blood sam-
ples in the study. All experiments were preformed in accordance with the approved guidelines and regulations.
STS selection and probe design. Two thousand three hundred fourteen STSs, including 2029 single-copy 
STSs and 285 two-copy STSs were extracted from the UniSTS databases (NCBI MapView). ,Two thousand three 
hundred and seventy six STSs including 2026 single-copy STSs and 350 multi-copy STSs were extracted from the 
UCSC database. In total, 2657 non-redundant different STSs from these two sources were selected to blot against 
an hg19 reference. The STSs with alignments exceeding 95% identity and 95% coverage were selected, and these 
STSs included 1657 STSs with unique mapping locations that constituted a net length of 467,535 bp and 603 STS 
with multiple alignment positions (selected from only the AZF region) that constituted 193,911 bp. Overall, 2260 
STSs with a net length of 660,598 bp were ultimately selected for probe design, and there was a high density of 
1063 STSs in the AZF region. The probes were designed following the standard pipeline of Nimblegen (Roche 
Nimblegen Inc., USA) with adjustments of the parameters to recover the majority of the target STSs.
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Library construction and high throughput sequencing for Y-chromosomal STSs. Genomic DNA 
was extracted from the peripheral blood with a commercial kit and was then fragmented to 200 bp by Covaris 
S2 (Covaris Inc.), end repaired, A-tailed and adaptor ligated. The product was purified with Ampure beads and 
amplified with 6 cycles of ligation-mediated PCR. Sequence capture was performed according to the manufactur-
er’s protocol (Roche Nimblegen Inc.), and the enriched product was further amplified by PCR. The sequencing 
libraries were then subjected to quality assessment, quantification, and cluster generation and then sequenced on 
the Hiseq 2000 platform (Illumina Inc.) with 100-bp paired-end protocols.
Data alignment, filtering and deletion detection. The sequencing reads were first processed to remove 
the sequencing adaptors and discard the low quality reads and were then were aligned to hg19 of the human 
reference genome with SOAP2 version 2.20. PCR and optical duplicate reads were removed, and the mean and 
median depths of each target STS were then calculated. The samples and STSs with extreme depths were defined 
as outliers according to a 1.5 × IQR rule (i.e., an interquartile range rule) and were removed. Additionally, we 
determined that there was sufficient statistical power to qualify a STS for deletion identification only if its depth 
distribution was sufficiently high among all of the samples; in other words, the method performed well in the 
capture of undeleted samples. After data modeling (data not shown), we applied a more stringent cutoff of 15x for 
the median depths of the STSs. The depth of each sample was normalized by dividing it by the mean depth of all of 
its STSs. For each sample, the standard deviation of the normalized depth was calculated across all of the sample’s 
STSs, and samples with standard deviations > 0.7 were excluded.
For m STS in n samples, Dij represented the mean depth of all of the bases of the jth STS in the ith sample; thus,
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where µ⋅j and δ⋅j are the mean and standard deviation of the depth of the jth STS, respectively. Therefore, the prob-
ability of Dij under an approximated normal distribution of the depth of the jth STS was as follows:
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We used ( )log P Dij  as our first predictor in the SVM model. For the second predictor, we had the following:
/ = / ( )⋅Depth RMD D M 4ij j
where ⋅Mi  ⋅Mj is the median of , , …,D D D1j 2j nj, which were the depths of the jth STS among all of the samples. 
Similarly, we used
/ = / ( )⋅Depth SMD D M 5ij i
as our third predictor. ⋅Mi  is the median of , , …,D D D1j 2j im.
Thus, the SVM model
= ( ( ), / , / ) ( )Y f logP D Depth RMD Depth SMD 6ij
was trained and used for deletion prediction. The best combination of C and sigma parameters was selected with 
a grid search with exponentially growing C and sigma sequences (i.e., 2−5, 2−4, 2−3, .. 215; Supplementary Fig. 3). 
The concordance rates of the different combinations of parameters were calculated via 1000 repetition 4-fold cross 
validation using the PCR-validated data from 134 STSs (Table S).
Merge of the STS deletions to locate the boundaries. We attempted to merge the continuous STS 
deletions to locate the deletion boundaries. The principle was to merge the continuous unique deleted STSs 
and the undeleted multi-copy STSs for which the inter-distance was within a certain range, and there were no 
non-deleted single-copy STS in the merged products. To achieve this goal, we first evaluated the inter-distance 
distribution of the STS probes (Supplementary Fig. 4) and found that the peak was shorter than 5 kb, and the 
95th percentile of the distance was approximately 50 kb. To balance the possibilities of disconnecting continuous 
deletions and connecting discontinuous deletions, we set 100 kb as the cutoff for connecting the deleted STSs. 
Therefore, the continuously deleted STSs with less than 100 kb in distance were connected to represent longer 
deletions that composed all of the STSs. Discontinuously deleted STSs of less than 100 kb with only non-deleted 
multi-copy STSs between them were also connected because the multi-copy STSs might lose copies that our 
method was not intended to detect. The connections were applied, the deletion boundaries were inferred from 
the reference genome, and the approximated boundaries were estimated based on the genomic coordinates of the 
deleted STSs at the borders of the connections.
PCR validation. The characterizations of the Y-chromosome microdeleted patients were validated by ampli-
fying the STS markers with a male control sample, a female sample, and a blank sample. The STSs were sY3127, 
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sY1241, sY1783, sY82, sY1180, sY84, sY709, sY1066, sY744, sY1264, sY1227, sY1302, sY143, sy1258, sY1259, 
sY1161, sY1160, sY1058, sY1616, sY1197, sY1161, sY1192, sY1191, sY1189, sY1291, and sY1206. Additionally, 
100 NOA patients and 100 normal controls were randomly selected for validation using sY1191-, sY1192-, 
sY1189-, and sY1291-specific primers. All of the PCR assays were performed in a total volume of 25 μ l that con-
tained 100 ng of each DNA sample with the primers for the SRY gene as positive controls. The cycling protocol 
was as follows: 5 min at 94 °C, followed by 35 cycles as 94 °C for 45 s, 55–62 °C for 45–60 s and 60 s at 72 °C, and 
72 °C for 5 min. The PCR products were analyzed by electrophoresis at 100 V on 2% agarose gels.
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